• Molecular NameSevelamer
  • SynonymNA
  • Weight149.621
  • Drugbank_IDDB00658
  • ACS_NO52757-95-6
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)0.25
  • pkaN/A
  • LogD (pH=7, predicted)0.25
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.62
  • LogSw (predicted, AB/LogsW2.0)142.48
  • Sw (mg/ml) (predicted, ACD/Labs)21.99
  • No.of HBond Donors0
  • No.of HBond Acceptors1
  • No.of Rotatable Bonds1
  • TPSA21.76
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure.
  • Absorption_valueN/A
  • Absorption (description)Not absorbed following oral administration, however no absorption studies have been performed in patients with renal disease.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • Excretionfaecal 100%
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySevelamer has been given to normal healthy volunteers in doses of up to 14 grams per day for eight days with no adverse effects. Sevelamer has been given in average doses up to 13 grams per day to hemodialysis patients. There are no reported overdosages of sevelamer in patients. Since sevelamer is not absorbed, the risk of systemic toxicity is low.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A